

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: Dieter Riemann, Ph.D.

Role(s) in Work Group: Member, Sleep-Wake Disorders Work Group

Institutional Affiliation(s): Department of Psychiatry & Psychotherapy, Freiburg University Medical Center, Germany

City, State: Freiburg, Baden-Württemberg, Germany

Biographical Sketch:

Dieter Riemann, PhD

Member DSM-V Work Group on Sleep Disorders

Professor of Clinical Psychology and Psychophysiology and Section Head at the Department of Psychiatry and Psychotherapy of Freiburg University Medical Center, Germany. Freiburg, Germany

Dr. Riemann was appointed Professor of Clinical Psychology and Psychophysiology at the Department of Psychiatry and Psychotherapy at Freiburg University Medical Center in 1993. In his capacity as a Section Head (since 2000) he directs the Center for Sleep Research and Medicine at the Department. He is also a member of the Faculty for Psychology at Freiburg University and since 2006 he is Adjunct Professor of Psychiatry at the University of Rochester, NY, School of Medicine and Dentistry. His present research focuses on sleep in psychiatric conditions and insomnia. He has been involved in psychopharmacological research, i.e. the impact of several drugs (antidepressant, hypnotics) on sleep and he has pioneered the introduction of cognitive-behavioral therapy for the treatment of insomnia in German speaking countries. Most recently, his work concentrated on neurobiological aspects of insomnia integrating neuroendocrinological, neuroimmunological, electro- and neurophysiological and neuroimaging techniques in his repertoire of research methods.

Dr. Riemann graduated in Psychology from the University of Munich in 1988 ("Diplom in Psychology," equivalent to Master); he received his PhD in 1988 from the University of Konstanz in 1988 and successfully passed his Habilitation in 1992 at the University of Heidelberg. In 1999 he qualified as a Psychological Psychotherapist (focus: Behavioral Therapy) and was certified by the Governmental Presidency in Stuttgart. In 2004 he was acknowledged as a Supervisor for Behavioral Therapy (Governmental Presidency Stuttgart).

He started out his professional career as a Research Fellow at the Max Planck Institute for Psychiatry in Munich followed by an Assistant Professorship at the Central Institute for Mental Health in Mannheim till he was appointed Full Professor in Freiburg in 1993.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
German Sleep Society	2002 – 2006	Board member
European Sleep Research Society	2004 – 2008	Member of Scientific Committee

German Sleep Society, work group Insomnia	1993 – 2006	Head of work group
German Sleep Society, commission on scientific coordination	1998 – 2006	Head of the commission

The two tables below represent Dr. Riemann's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Riemann has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Takeda, GLG	2005 - 2007	1
Cephalon, Takeda, VerlaPharm, Actelion	2005 - 2007	3
Weinmann, Takeda, Sanofi-Aventis, Cephalon, Merz Pharmaceuticals, Lundbeck, Servier and several Institutes for Behavioral Therapy in Germany (FAVT, IFT, HRI, LPTW)	2005 - 2007	4

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Lundbeck, SKB	2008	1
Actelion, Organon	2008	3
Sanofi-Synthelabo, Cephalon, Lundbeck, Boehringer and several Institutes for Behavioral Therapy (FAVT, IFT, AVM, HRI, LPTW)	2008	4